NPRA director Dr Roshayati Mohamad Sani said five of the cases required hospitalisation while the remaining one, who is understood to have had an underlying health condition, was brought in dead (BID).

“All five have been discharged after receiving further treatment. Two of whom have fully recovered while the other three are still recovering.

“The BID case had a pre-existing condition but investigations are still going on to determine if it was linked to the vaccine,” she said during a media briefing today.

Roshayati said as of March 11, a total of 182 AEFI cases had been reported involving children out of a total of 1,097,425 Covid-19 vaccinations administered to those aged five to 11.

This was at a rate of 0.17 reports per 1,000 doses administered, with 96.7% of the reports being non-serious cases.

She added that Malaysia’s AEFI reporting rate for the same age group was on par with that of other countries, namely Canada (0.19 reports per 1,000 doses) and Australia (0.7 reports per 1,000 doses).

Meanwhile, as per the NPRA’s latest statistics dated March 11, the agency had received a total of 25,746 AEFI reports due to the Covid-19 vaccine, including 1,411 among booster dose recipients and the 182 reports involving children, which is at a rate of 379 reports per million doses.

Roshayati said 93% of the reports were non-serious cases, with the agency categorising 1,789 as serious (a rate of 26 reports per million doses).

The agency deems non-serious cases of AEFI as vaccine recipients experiencing side effects, including fever, pain at the injection area, headache, muscle pain, and fatigue.

Serious cases are categorised as those involving hospitalisation, life-threatening conditions, or those suspected to have resulted in death.

CLICK HERE FOR THE LATEST DATA ON THE COVID-19 SITUATION IN MALAYSIA